Is Sentinel Lymph Node Biopsy Reliable After Recent Oncoplastic Breast Reduction?

Am Surg. 2023 May;89(5):2056-2058. doi: 10.1177/00031348211023408. Epub 2021 May 31.

Abstract

An oncoplastic breast reduction may disrupt normal lymphatic drainage and make subsequent identification of the sentinel lymph nodes (SLNs) unreliable. There are little data on the success rate of sentinel lymph node biopsy (SLNB) after recent oncoplastic breast reduction, and there is no agreement on whether SLNB should be done at the time of the partial mastectomy and reduction for ductal carcinoma in situ (DCIS). The primary goals of this study were to evaluate the identification rate of SLNB after recent oncoplastic or functional breast reduction and to examine recurrence rates in this setting. Results reveal SLNB is feasible in this setting. At least one SLN was found in all patients, and there were no recurrences with an average follow-up of 34 months.

Keywords: reduction; sentinel lymph node biopsy.

MeSH terms

  • Axilla / surgery
  • Breast Neoplasms* / pathology
  • Breast Neoplasms* / surgery
  • Female
  • Humans
  • Lymph Nodes / pathology
  • Lymphatic Metastasis / pathology
  • Mammaplasty*
  • Mastectomy
  • Sentinel Lymph Node Biopsy / methods